Related Experiment Video
Updated: May 5, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Methamphetamine regulates microglial polarization and glycolytic activity to promote Parkinson's disease through the
Yanghong Zou1, Chunhai Zhang2, Hui Bian3
1The Second Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China; NHC Key Lab of Drug Addiction Medicine (Kunming Medical University), Kunming 650500, Yunnan, China.
Background:
The abuse of methamphetamine (METH) is associated with an increased risk of Parkinson's disease (PD), whereas microglial polarization and glucose metabolism disorders are closely related to the progression of PD. This study aimed to investigate the specific molecular mechanism underlying the promotion of PD progression by METH through the regulation of microglial polarization and glycolysis.
Methods:
METH-induced C57BL/6 mice and BV2 cells were used to construct PD-like neurotoxicity animal and cell models for experimental investigation. Behavioral tests, immunohistochemistry and Nissl staining were used to assess the behavioral ability and neuronal damage of the animals. The levels of related proteins, inflammatory cytokines and glycolysis were detected using immunofluorescence, ELISA, Western blotting, and CCK-8 assays.
Results:
METH treatment significantly promoted behavioral disorders in PD mice, reduced the number of TH-positive neurons, and aggravated neuronal damage in the substantia nigra (SN). In addition, METH decreased the M2 marker proteins Arg-1 and CD206 and increased the M1 marker proteins iNOS and CD86; the proinflammatory cytokines TNF-α, IL-β, and IL-6; and glucose uptake, glucose consumption and lactic acid production, thus promoting M1 polarization and glycolytic activity in BV2 cells. In terms of the underlying molecular mechanism, METH treatment significantly increased the level of LPA. METH promotes LPA expression via upregulation of LIPH expression, and activates the PI3K/AKT pathway. Knockdown of LIPH or treatment with BrP-LPA reduces the ability of METH to promote M1 microglial polarization and glycolytic activity. Furthermore, the addition of the PI3K/AKT signaling pathway activator 740 YP weakened the inhibitory effect of BrP-LPA on the above process.
Conclusion:
METH may promote M1 polarization and glycolytic activity in microglia by activating LIPH/LPA/PI3K/AKT signaling, thus promoting the progression of PD.
Insights
Methamphetamine (METH) abuse promotes Parkinson's disease (PD) progression by activating microglial M1 polarization and glycolysis via the LIPH/LPA/PI3K/AKT pathway. This mechanism exacerbates neuroinflammation and neuronal damage in PD.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Methamphetamine (METH) abuse is linked to increased Parkinson's disease (PD) risk.
- Microglial polarization and altered glucose metabolism are key factors in PD progression.
Purpose of the Study:
- To elucidate the molecular mechanism by which METH promotes PD progression.
- Investigate METH's role in regulating microglial polarization and glycolysis.
Main Methods:
- Established METH-induced PD models in C57BL/6 mice and BV2 cells.
- Assessed behavioral changes, neuronal damage, microglial polarization markers, inflammatory cytokines, and glycolytic activity.
- Utilized immunofluorescence, ELISA, Western blotting, and CCK-8 assays.
Main Results:
- METH treatment worsened PD-like behaviors and substantia nigra neuronal damage in mice.
- METH induced M1 microglial polarization and increased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) while decreasing M2 markers.
- METH enhanced microglial glycolytic activity and activated the LIPH/LPA/PI3K/AKT signaling pathway.
Conclusions:
- METH promotes M1 microglial polarization and glycolytic activity.
- The LIPH/LPA/PI3K/AKT signaling pathway mediates METH's pro-PD effects.
- Targeting this pathway may offer therapeutic strategies for METH-associated PD.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:24Parkinson Disease ll: Pathophysiology